Abstract
Background and aim: HCC is the third cause of cancer related death worldwide and the fifth most common cancer in the world with an increasing incidence in some areas like Europe, USA and the Gulf region. In this study patients with advanced HCC in both group child pugh A and B were treated with sorafenib. Methods: This is a retrospective observational study to assess the safety and effectiveness of sorafenib in patients with advanced HCC child pugh A and B, who failed local palliative ablation therapy or where not eligible for such therapy. Forty six patients included. Results: in both child pugh A and B group the sorafenib was well tolerated and survival was improved but it was more pronounced in the Child pughA group. Conclusion: This is the first study including such high percentage (47%) of child B group to be treated with sorafenib. compared with international data there was improved overall survival in both groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
